tiprankstipranks
Qlife Holding AB (SE:QLIFE)
:QLIFE
Want to see SE:QLIFE full AI Analyst Report?

Qlife Holding AB (QLIFE) AI Stock Analysis

0 Followers

Top Page

SE:QLIFE

Qlife Holding AB

(QLIFE)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 5.2)
Rating:46Neutral
Price Target:
kr2.00
▼(-33.55% Downside)
Action:Reiterated
Date:05/23/26
The score is held down primarily by very weak financial performance (tiny and declining revenue, deeply negative margins, persistent cash burn, and high leverage/financing risk). Technicals provide some offset with modest near-term improvement versus key moving averages and largely neutral momentum, but valuation remains unattractive/unclear due to negative earnings and no dividend data.
Positive Factors
Proprietary platform for near‑patient diagnostics
Qlife's core offering is an integrated platform of instruments, assays and software for rapid, near‑patient molecular testing. That platform-based approach creates technical differentiation and product stickiness, aligning with a durable structural shift toward decentralized diagnostics if commercial adoption scales.
Negative Factors
Tiny, declining revenue base
Revenue run‑rate is extremely low and falling, indicating weak commercial traction. Such a small base cannot support fixed R&D and commercial costs, making sustainable margin expansion unlikely without a material and sustained lift in sales or adoption of the platform.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary platform for near‑patient diagnostics
Qlife's core offering is an integrated platform of instruments, assays and software for rapid, near‑patient molecular testing. That platform-based approach creates technical differentiation and product stickiness, aligning with a durable structural shift toward decentralized diagnostics if commercial adoption scales.
Read all positive factors

Qlife Holding AB (QLIFE) vs. iShares MSCI Sweden ETF (EWD)

Qlife Holding AB Business Overview & Revenue Model

Company Description
Qlife Holding AB (QLIFE) is a biotechnology company based in Sweden, specializing in the development of advanced diagnostic tools aimed at improving patient care and health outcomes. The company focuses on innovative solutions in the healthcare se...
How the Company Makes Money
null...

Qlife Holding AB Financial Statement Overview

Summary
Very weak fundamentals: TTM revenue is extremely small (239k) and down sharply (-27%), profitability is deeply negative (negative gross profit and very large operating/net losses), and cash burn remains heavy (TTM operating cash flow -12.7m; free cash flow -11.2m). Balance sheet risk is elevated with high leverage (~8.7m debt vs ~1.9m equity, ~4.6x) and a history of negative equity despite turning positive in TTM.
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
11
Very Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue239.00K324.00K50.00K244.00K17.99M39.61M
Gross Profit-8.87M-19.38M-158.00K-6.31M-10.75M44.54M
EBITDA-18.41M-18.11M-12.46M-150.50M-78.05M-35.13M
Net Income-20.50M-20.56M-55.98M-159.96M-93.14M-38.80M
Balance Sheet
Total Assets14.80M9.63M11.64M39.05M192.65M193.44M
Cash, Cash Equivalents and Short-Term Investments6.63M1.42M2.71M1.66M14.55M73.46M
Total Debt8.71M8.55M8.70M20.25M52.44M4.72M
Total Liabilities12.89M17.14M13.07M62.17M101.50M30.26M
Stockholders Equity1.91M-7.51M-1.43M-23.12M91.15M132.50M
Cash Flow
Free Cash Flow-11.19M0.00-54.17M-62.64M-90.67M-52.82M
Operating Cash Flow-12.66M-15.60M-37.37M-41.80M-47.73M-26.05M
Investing Cash Flow0.000.00-16.80M-20.84M-42.94M-26.77M
Financing Cash Flow16.61M14.30M55.23M49.00M32.73M106.02M

Qlife Holding AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.01
Price Trends
50DMA
1.96
Positive
100DMA
2.06
Negative
200DMA
2.38
Negative
Market Momentum
MACD
<0.01
Negative
RSI
54.74
Neutral
STOCH
75.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Positive. The current price of 3.01 is above the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.96, and above the 200-day MA of 2.38, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.74 is Neutral, neither overbought nor oversold. The STOCH value of 75.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:QLIFE.

Qlife Holding AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
kr149.56M-1.9668.59%
46
Neutral
kr57.75M-0.68437.24%268.54%94.27%
44
Neutral
kr57.58M-8.36-9.56%51.30%
43
Neutral
kr38.13M-1.63-60.56%27.31%6.31%
41
Neutral
kr48.16M-1.14-50.21%-104.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:QLIFE
Qlife Holding AB
1.91
-0.28
-12.69%
SE:SPEC
SpectraCure AB
0.09
-0.10
-52.36%
SE:LXB
Luxbright AB
0.17
-0.59
-77.79%
SE:HEART
Scandinavian Real Heart AB
18.15
4.15
29.64%
SE:SDOS
ScandiDos AB
1.01
-0.29
-22.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 23, 2026